Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies

Table 2 Treatment-related TEAEs with grade ≥ 3 in AFM11-101

Adverse event	AFM11 dose level (μg/kg)
Adverse event	0.0003^a n = 1	0.001^a n = 8	0.003^a n = 1	0.003^b n = 1	0.003^c n = 1	0.01^c n = 2	0.03^c n = 2	Total n = 16
Patients with at least 1 TEAE grade ≥ 3	0	1	1	1	0	0	2	5
Cognitive disorder	0	0	1	0	0	0	0	1
Depressed level of consciousness	0	0	0	0	0	0	1	1
Encephalopathy	0	1	0	0	0	0	0	1
Neurotoxicity	0	0	0	0	0	0	1	1
Seizure	0	0	0	0	0	0	1	1
Respiratory failure	0	0	0	0	0	0	2	2
Lymphopenia	0	1	0	0	0	0	0	1
Tachycardia	0	0	0	1	0	0	0	1
Hypotension	0	0	0	0	0	0	1	1
Confusional state	0	0	0	1	0	0	0	1

ISSN: 1745-6215